NATCO receives final approval for Tipiracil Hydrochloride and Trifluridine for the US market

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) has announced final approval for its Abbreviated New Drug Application (ANDA) for Tipiracil Hydrochloride and Trifluridine Tablets (generic for Lonsurf®) from the U.S. Food and Drug Administration (USFDA). Lonsurf® is sold in the US by Taiho Oncology Inc.

Natco believes it is one of the First-to-File for the product and may be eligible for a 180-day exclusivity at the time of launch. Lonsurf® is indicated primarily for the treatment of colorectal cancer. As per IQVIA data, Lonsurf® had generated annual sales of $211 million in USA during the twelve months ending December 2022.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 639.60 as compared to the previous close of Rs. 619.40. The total number of shares traded during the day was 41467 in over 1337 trades.

The stock hit an intraday high of Rs. 643.25 and intraday low of 619.45. The net turnover during the day was Rs. 26349178.00.

*All brand names and trademarks are the property of their respective owners.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 USFDA ANDAApproval TipiracilHydrochloride TrifluridineTablets